Detailed Review,Mounjaro is set to be reconsidered for Pharmaceutical Benefits Scheme (PBS) reimbursement

The question of is tirzepatide on PBS in Australia is a significant one for many Australians seeking effective treatments for type 2 diabetes and obesity. While tirzepatide has gained considerable attention, its availability through the Pharmaceutical Benefits Scheme (PBS) is nuanced and evolving. Currently, Mounjaro (tirzepatide) is not broadly listed on the PBS for general weight management, though its status is under continuous review.

Understanding Tirzepatide and its Approval in Australia

Tirzepatide, marketed as Mounjaro, is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. It has been approved by the Therapeutic Goods Administration (TGA) in Australia for the treatment of type 2 diabetes and, more recently, for obesity management. The SURMOUNT trials have demonstrated significant efficacy, with tirzepatide resulting in substantial weight loss, often around 15% in adults with overweight or obesity. This has led to increased interest in its accessibility for a wider patient population.

The PBS Landscape for Tirzepatide

The PBS in Australia is a government scheme that subsidises the cost of a wide range of prescription medications, making them more affordable for Australians. For a medication to be listed on the PBS, it undergoes a rigorous assessment by the Pharmaceutical Benefits Advisory Committee (PBAC). This committee evaluates the clinical effectiveness, safety, and cost-effectiveness of the drug compared to existing treatments.

Recent information indicates that while tirzepatide has been approved by the TGA, its PBS listing has faced challenges. The PBAC has considered submissions for tirzepatide, with some meetings in July 2023 and November 2024 noted in relation to its status. A significant factor in PBS listing decisions is the price of the medication. Reports suggest that the drug company, Lilly, has indicated that the price proposed for Mounjaro on the PBS was too low, leading to a refusal to list it under those terms.

There have been instances where Mounjaro (tirzepatide) has been recommended for PBS reimbursement with certain restrictions, particularly for type 2 diabetes. However, these recommendations have sometimes come with "unviable and unsustainable" pricing conditions, preventing a broad listing. The PBAC has also noted that tirzepatide is currently available through the private market, and a PBS listing would indeed improve equity of access.

Current Availability and Cost

As of current information, tirzepatide is available in Australia through private prescriptions. This means that patients will incur the full cost of the medication, which can range significantly. For example, Mounjaro (tirzepatide) is listed as Not PBS listed with prices estimated between $285–$690. This contrasts with medications like Ozempic (semaglutide), which is PBS listed but restricted, with costs around $31.60 per month on the PBS or $134.27 per month privately. Wegovy (semaglutide), another weight-loss medication, is also Not PBS listed and can cost between $269–$390.

Future Prospects and Related Searches

The push for weight-loss drugs like tirzepatide to be listed on the PBS is intensifying. The Health Minister has actively sought advice from the PBAC on equitable access to medicines for obesity. This suggests a growing recognition of the public health imperative to address obesity and its associated conditions.

Several related searches highlight the ongoing public interest and uncertainty:

* "When will Mounjaro be on the PBS in Australia"

* "Is Ozempic on the PBS in Australia"

* "Mounjaro Australia cost PBS"

* "Tirzepatide PBS"

* "When will Wegovy be on PBS in Australia"

* "Is Mounjaro on PBS for type 2 diabetes"

* "Mounjaro PBS 2026"

* "Is Wegovy on the PBS in Australia"

These searches reflect a desire for clarity on the PBS status of these transformative medications. While Mounjaro (tirzepatide) is currently not broadly available on the PBS, the ongoing discussions and reviews indicate that its inclusion is a possibility for the future, especially as more data emerges regarding its long-term effectiveness and cost-effectiveness for Australians. The Medicine Status Website and healthdirect are valuable resources for staying updated on the latest information regarding medication status and warnings, including potential risks like suicidal thoughts associated with the GLP-1 class of medicines, as issued by the TGA.

In conclusion, while tirzepatide is approved in Australia for specific indications, its PBS listing remains